Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Next Previous
X
Search
Trial Profile

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efpeglenatide (Primary) ; Liraglutide
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EXCEED; EXCEED 203
  • Sponsors Hanmi Pharmaceutical

    • Most Recent Events

    • 18 Jul 2019 Safety and efficacy results published in the Diabetes Care.
    • 11 Jun 2019 Results of post-hoc sub analysis stratified by baseline characteristics, presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 11 Jun 2019 Subanalysis results from EXCEED 203 study were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top